RevolKa Ltd., a biotech company, has announced the completion of its collaborative drug discovery project with Sumitomo Pharma Co. for rare diseases. The project was completed within the agreed time frame and lead candidates were identified using RevolKa's proprietary technology platform called aiProtein®, which integrates directed protein evolution technology with artificial intelligence (AI). ..
AbbVie has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for atogepant, an oral calcitonin gene-related peptide receptor antagonist, as a prophylaxis of migraine in adults who have four or more migraine days per month. If approved by the European Commission, AbbVie will be the only company to offer a once-daily treatment sp..
HiFiBiO Therapeutics has announced that the first patient has been dosed with HFB200301, a monoclonal antibody in combination with tislelizumab for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. The Phase 1a/b study will investigate the safety and tolerability of this combination therapy, and data from the trial w..
Q BioMed Inc., a biotech acceleration and commercial stage company, has provided an update to shareholders regarding its financials and OTC listing compliance. The company was unable to file complete audited financials for 2022 due to capital constraints and costs associated with the audit process. As a result, it filed an un-audited annual report for 2022 and Q1 2023 but was downgraded to the '..
Ocean Biomedical (NASDAQ: OCEA) has been granted a European patent for its breakthrough Idiopathic Pulmonary Fibrosis discovery. The announcement comes after the European Patent Office granted Dr. Jack A. Elias, MD, Ocean Biomedical's Scientific Co-founder, a patent for Methods and Compositions relating to the treatment of fibrosis using Ocean’s anti-Chitinase 1 small molecule candidate (“Small ..
Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate ..
Jasper Therapeutics has announced the dosing of the first patient in a Phase 1 trial for Briquilimab, an antibody therapy targeting c-Kit (CD117) for lower-risk myelodysplastic syndromes (LR-MDS). The single-arm Phase 1 trial will evaluate briquilimab's safety and tolerability as a second-line therapy in subjects with LR-MDS. The trial will employ a dose escalation design to identify the optimal..
